1. Coronavirus disease (COVID-19), (n.d.). https://www.who.int/news-room/fact-sheets/detail/coronavirus-disease-(covid-19) (accessed February 13, 2024).
2.
Akbarialiabad H, Taghrir MH, Abdollahi A, et al. Long COVID, a comprehensive systematic scoping review. Infection 2021; 49: 1163-86.
3.
Giussani G, Westenberg E, Garcia-Azorin D, et al. Prevalence and trajectories of post-COVID-19 neurological manifestations: a systematic-review and meta-analysis. Neuroepidemiology 2024; 58: 120-33.
4.
Schurr M, Junne F, Martus P, et al. SARS-CoV-2 infection is associated with physical but not mental fatigue – findings from a longitudinal controlled population-based study. J Psychosom Res 2024; 178: 111598.
5.
Premraj L, Kannapadi NV, Briggs J, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis. J Neurol Sci 2022; 434: 120162.
6.
Pinzon RT, Wijaya VO, Al Jody A, et al. Persistent neurological manifestations in long COVID-19 syndrome: a systematic review and meta-analysis. J Infect Public Health 2022; 15: 856-69.
7.
Ceban F, Ling S, Lui LMW, et al. Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun 2022; 101: 93-135.
8.
Crook H, Raza S, Nowell J, et al. Long COIVID-mechanisms, risk factors, and management. BMJ 2021; 374: n1648.
9.
Song WJ, Hui CKM, Hull JH, et al. Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses. Lancet Respir Med 2021; 9: 533-44.
10.
Kavanagh E. Long Covid brain fog: a neuroinflammation phenomenon? Oxf Open Immunol 2022; 3: iqac007.
11.
Eroğlu İ, Eroğlu BÇ, Güven GS. Altered tryptophan absorption and metabolism could underlie long-term symptoms in survivors of coronavirus disease 2019 (COVID-19). Nutrition 2021; 90: 111308.
12.
Al-Hakeim HK, Abed AK, Almulla AF, et al. Anxiety due to Long COVID is partially driven by activation of the tryptophan catabolite (TRYCAT) pathway. Asian J Psychiatr 2023; 88: 103723.
13.
Platten M, Nollen EAA, Röhrig UF, et al. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov 2019; 18: 379-401.
14.
Chen Y, Guillemin GJ. Kynurenine pathway metabolites in humans: disease and healthy states. Int J Tryptophan Res 2009; 2: 1-19.
15.
Yamashita M. Potential role of neuroactive tryptophan metabolites in central fatigue: establishment of the fatigue circuit. Int J Tryptophan Res 2020; 13: 1178646920936279.
16.
Chuang HJ, Lin CW, Hsiao MY, et al. Long COVID and rehabilitation. J Formos Med Assoc 2024; 123 Suppl 1: S61-S69.
17.
Chee YJ, Fan BE, Young BE, et al. Clinical trials on the pharmacological treatment of long COVID: a systematic review. J Med Virol 2023; 95: e28289.
18.
Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023; 21: 133-46.
19.
Srisurapanont K, Samakarn Y, Kamklong B, et al. Blue-wavelength light therapy for post-traumatic brain injury sleepiness, sleep disturbance, depression, and fatigue: a systematic review and network meta-analysis. PLoS One 2021; 16: e0246172.
20.
Racz E, Prens EP. Phototherapy and photochemotherapy for psoriasis. Dermatol Clin 2015; 33: 79-89.
21.
Lim HW, Silpa-archa N, Amadi U, et al. Phototherapy in dermatology: a call for action. J Am Acad Dermatol 2015; 72: 1078-80.
22.
Weinstabl A, Hoff-Lesch S, Merk HF, von Felbert V. Prospective randomized study on the efficacy of blue light in the treatment of psoriasis vulgaris. Dermatology 2011; 223: 251-9.
23.
Pfaff S, Liebmann J, Born M, et al. Prospective randomized long-term study on the efficacy and safety of UV-free blue light for treating mild psoriasis vulgaris. Dermatology 2015; 231: 24-34.
24.
Liebmann J, Born M, Kolb-Bachofen V. Blue-light irradiation regulates proliferation and differentiation in human skin cells. J Invest Dermatol 2010; 130: 259-69.
25.
Awakowicz P, Bibinov N, Born M, et al. Biological stimulation of the human skin applying health promoting light and plasma sources. Contrib. Plasma Phys 2009; 49: 641-7.
26.
Fischer MR, Abel M, Lopez Kostka S, et al. Blue light irradiation suppresses dendritic cells activation in vitro. Exp Dermatol 2013; 22: 558-60.
27.
Do A, Li VW, Huang S, et al. Blue-light therapy for seasonal and non-seasonal depression: a systematic review and meta-analysis of randomized controlled trials. Can J Psychiatry 2022; 67: 745-54.
28.
Connolly LJ, Rajaratnam SMW, Murray JM, et al. Home-based light therapy for fatigue following acquired brain injury: a pilot randomized controlled trial. BMC Neurol 2021; 21: 262.
29.
Wu HS, Gao F, Yan L, Given C. Evaluating chronotypically tailored light therapy for breast cancer survivors: preliminary findings on fatigue and disrupted sleep. Chronobiol Int 2022; 39: 221-32.
30.
Paradiso B, Limback C, Su T, et al. Editorial: an update on neurological disorders post COVID-19 infection. Front Neurol 2023; 14: 1229843.
31.
Martínez-Mármol R, Giordano-Santini R, Kaulich E, et al. SARS-CoV-2 infection and viral fusogens cause neuronal and glial fusion that compromises neuronal activity. Sci Adv 2023; 9: eadg2248.
32.
Sohn CH, Lam RW. Update on the biology of seasonal affective disorder. CNS Spectr 2005; 10: 635-46.
33.
Berson DM, Dunn FA, Takao M. Phototransduction by retinal ganglion cells that set the circadian clock. Science 2002; 295: 1070-3.
34.
Pail G, Huf W, Pjrek E, et al. Bright-light therapy in the treatment of mood disorders. Neuropsychobiology 2011; 64: 152-62.
35.
Badawy AAB. Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. Int J Tryptophan Res 2017; 10: 1178646917691938.
36.
Al-Hakeim HK, Khairi Abed A, Rouf Moustafa S, et al. Tryptophan catabolites, inflammation, and insulin resistance as determinants of chronic fatigue syndrome and affective symptoms in long COVID. Front Mol Neurosci 2023; 16: 1194769.
37.
Maes M, Rief W. Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatry Res 2012; 196: 243-9.
38.
Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012; 13: 465-77.
39.
Colín-González AL, Maldonado PD, Santamaría A. 3-Hydroxykynurenine: an intriguing molecule exerting dual actions in the central nervous system. Neurotoxicology 2013; 34: 189-204.
